Exploring 7β-amino-6-nitrocholestens as COVID-19 antivirals: in silico, synthesis, evaluation, and integration of artificial intelligence (AI) in drug design: assessing the cytotoxicity and antioxidant activity of 3β-acetoxynitrocholestane†

IF 3.597 Q2 Pharmacology, Toxicology and Pharmaceutics
MedChemComm Pub Date : 2024-09-26 DOI:10.1039/D4MD00257A
Shahabuddin, Uzma, Mohammad Azam, Mehtab Parveen, Nurul Huda Abd Kadir, Kim Min and Mahboob Alam
{"title":"Exploring 7β-amino-6-nitrocholestens as COVID-19 antivirals: in silico, synthesis, evaluation, and integration of artificial intelligence (AI) in drug design: assessing the cytotoxicity and antioxidant activity of 3β-acetoxynitrocholestane†","authors":"Shahabuddin, Uzma, Mohammad Azam, Mehtab Parveen, Nurul Huda Abd Kadir, Kim Min and Mahboob Alam","doi":"10.1039/D4MD00257A","DOIUrl":null,"url":null,"abstract":"<p >In light of the ongoing pandemic caused by SARS-CoV-2, effective and clinically translatable treatments are desperately needed for COVID-19 and its emerging variants. In this study, some derivatives, including 7β-aminocholestene compounds, and 3β-acetoxy-6-nitrocholesta-4,6-diene were synthesized, in quantitative yields from 7β-bromo-6-nitrocholest-5-enes (<strong>1–3</strong>) with a small library of amines. The synthesized steroidal products were then thoroughly characterized using a range of physicochemical techniques, including IR, NMR, UV, MS, and elemental analysis. Next, a virtual screening based on structures using docking studies was conducted to investigate the potential of these synthesized compounds as therapeutic candidates against SARS-CoV-2. Specifically, we evaluated the compounds' binding energy of the reactants and their products with three SARS-CoV-2 functional proteins: the papain-like protease, 3C-like protease or main protease, and RNA-dependent RNA polymerase. Our results indicate that the 7β-aminocholestene derivatives (<strong>4–8</strong>) display intermediate to excellent binding energy, suggesting that they interact strongly with the receptor's active amino acids and may be promising drug candidates for inhibiting SARS-CoV-2. Although the starting steroid derivatives; 7β-bromo-6-nitrocholest-5-enes (<strong>1–3</strong>) and one steroid product; 3β-acetoxy-6-nitrocholesta-4,6-diene (<strong>9</strong>) exhibited strong binding energies with various SARS-CoV-2 receptors, they did not meet the Lipinski Rule and ADMET properties required for drug development. These compounds showed either mutagenic or reproductive/developmental toxicity when assessed using toxicity prediction software. The findings based on structure-based virtual screening, suggest that 7β-aminocholestaines (<strong>4–8</strong>) may be useful for reducing the susceptibility to SARS-CoV-2 infection. The docking pose of compound <strong>4</strong>, which has a high score of −7.4 kcal mol<small><sup>−1</sup></small>, was subjected to AI-assisted deep learning to generate 60 AI-designed molecules for drug design. Molecular docking of these AI molecules was performed to select optimal candidates for further analysis and visualization. The cytotoxicity and antioxidant effects of 3β-acetoxy-6-nitrocholesta-4,6-diene were tested <em>in vitro</em>, showing marked cytotoxicity and antioxidant activity. To elucidate the molecular basis for these effects, steroidal compound 9 was subjected to molecular docking analysis to identify potential binding interactions. The stability of the top-ranked docking pose was subsequently assessed using molecular dynamics simulations.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 11","pages":" 3889-3911"},"PeriodicalIF":3.5970,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedChemComm","FirstCategoryId":"1085","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2024/md/d4md00257a","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

In light of the ongoing pandemic caused by SARS-CoV-2, effective and clinically translatable treatments are desperately needed for COVID-19 and its emerging variants. In this study, some derivatives, including 7β-aminocholestene compounds, and 3β-acetoxy-6-nitrocholesta-4,6-diene were synthesized, in quantitative yields from 7β-bromo-6-nitrocholest-5-enes (1–3) with a small library of amines. The synthesized steroidal products were then thoroughly characterized using a range of physicochemical techniques, including IR, NMR, UV, MS, and elemental analysis. Next, a virtual screening based on structures using docking studies was conducted to investigate the potential of these synthesized compounds as therapeutic candidates against SARS-CoV-2. Specifically, we evaluated the compounds' binding energy of the reactants and their products with three SARS-CoV-2 functional proteins: the papain-like protease, 3C-like protease or main protease, and RNA-dependent RNA polymerase. Our results indicate that the 7β-aminocholestene derivatives (4–8) display intermediate to excellent binding energy, suggesting that they interact strongly with the receptor's active amino acids and may be promising drug candidates for inhibiting SARS-CoV-2. Although the starting steroid derivatives; 7β-bromo-6-nitrocholest-5-enes (1–3) and one steroid product; 3β-acetoxy-6-nitrocholesta-4,6-diene (9) exhibited strong binding energies with various SARS-CoV-2 receptors, they did not meet the Lipinski Rule and ADMET properties required for drug development. These compounds showed either mutagenic or reproductive/developmental toxicity when assessed using toxicity prediction software. The findings based on structure-based virtual screening, suggest that 7β-aminocholestaines (4–8) may be useful for reducing the susceptibility to SARS-CoV-2 infection. The docking pose of compound 4, which has a high score of −7.4 kcal mol−1, was subjected to AI-assisted deep learning to generate 60 AI-designed molecules for drug design. Molecular docking of these AI molecules was performed to select optimal candidates for further analysis and visualization. The cytotoxicity and antioxidant effects of 3β-acetoxy-6-nitrocholesta-4,6-diene were tested in vitro, showing marked cytotoxicity and antioxidant activity. To elucidate the molecular basis for these effects, steroidal compound 9 was subjected to molecular docking analysis to identify potential binding interactions. The stability of the top-ranked docking pose was subsequently assessed using molecular dynamics simulations.

Abstract Image

探索作为 COVID-19 抗病毒药物的 7β-氨基-6-硝基胆甾烷:药物设计中的硅学、合成、评估和人工智能(AI)整合:评估 3β-acetoxynitrocholestane 的细胞毒性和抗氧化活性。
鉴于 SARS-CoV-2 正在引发的大流行,COVID-19 及其新变种亟需有效且可临床转化的治疗方法。在这项研究中,我们从 7β-溴-6-硝基胆甾烷-5-烯(1-3)与少量胺类化合物库中定量合成了一些衍生物,包括 7β-氨基胆甾烷化合物和 3β-乙酰氧基-6-硝基胆甾烷-4,6-二烯。然后使用一系列理化技术,包括红外光谱、核磁共振、紫外光谱、质谱和元素分析,对合成的类固醇产品进行了全面的表征。接下来,我们利用对接研究进行了基于结构的虚拟筛选,以研究这些合成化合物作为 SARS-CoV-2 候选治疗药物的潜力。具体来说,我们评估了这些化合物的反应物及其产物与三种 SARS-CoV-2 功能蛋白的结合能:木瓜蛋白酶样蛋白酶、3C 样蛋白酶或主蛋白酶以及 RNA 依赖性 RNA 聚合酶。我们的研究结果表明,7β-氨基胆甾烯衍生物(4-8)显示出中等到极好的结合能,表明它们与受体的活性氨基酸有很强的相互作用,可能是抑制 SARS-CoV-2 的有前途的候选药物。虽然起始甾体衍生物 7β-bromo-6-nitrocholest-5-enes (1-3)和一种甾体产物 3β-acetoxy-6-nitrocholesta-4,6-diene (9)与各种 SARS-CoV-2 受体的结合能很强,但它们并不符合药物开发所需的 Lipinski 规则和 ADMET 特性。在使用毒性预测软件进行评估时,这些化合物显示出诱变或生殖/发育毒性。基于结构的虚拟筛选结果表明,7β-氨基胆甾烷(4-8)可能有助于降低 SARS-CoV-2 感染的易感性。化合物 4 的对接姿势得分高达 -7.4 kcal mol-1,对其进行了人工智能辅助深度学习,生成了 60 个用于药物设计的人工智能设计分子。对这些人工智能分子进行了分子对接,以选择最佳候选分子进行进一步分析和可视化。体外测试了3β-乙酰氧基-6-硝基胆甾烷-4,6-二烯的细胞毒性和抗氧化作用,结果显示其具有明显的细胞毒性和抗氧化活性。为了阐明这些作用的分子基础,对甾体化合物 9 进行了分子对接分析,以确定潜在的结合相互作用。随后利用分子动力学模拟评估了排名靠前的对接姿势的稳定性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
MedChemComm
MedChemComm BIOCHEMISTRY & MOLECULAR BIOLOGY-CHEMISTRY, MEDICINAL
CiteScore
4.70
自引率
0.00%
发文量
0
审稿时长
2.2 months
期刊介绍: Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry. In 2020, MedChemComm will change its name to RSC Medicinal Chemistry. Issue 12, 2019 will be the last issue as MedChemComm.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信